沙美特罗/丙酸氟替卡松并噻托溴铵治疗重度稳定期COPD  

Efficacy of Salmeterol/Fluticasone Propionate Combined with Tiotropium in Treatment of Chronic Obstructive Lung Disease during Severe Stable Phase

作　　者：甄国粹[1] 罗志扬[1] 李敏菁[1] 梅湛强[1] 张培芳[1] 刘剑[1] 温业良[1] 谢毅强[2] 

机构地区：[1]佛山市第一人民医院呼吸内科,广东佛山528000 [2]海南医学院科研部,海口571199

出　　处：《临床误诊误治》2013年第8期93-96,共4页Clinical Misdiagnosis & Mistherapy

基　　金：海南省自然科学基金(812186)

摘　　要：目的探讨沙美特罗/丙酸氟替卡松联合噻托溴铵对重度稳定期慢性阻塞性肺疾病(chronic obstructive pulmo-nary disease,COPD)患者的疗效。方法选择69例重度稳定期COPD患者,随机分为治疗组35例和对照组34例。治疗组予沙美特罗/丙酸氟替卡松(50μg/250μg)吸入每天2次,噻托溴铵(18μg)吸入每天1次;对照组予噻托溴铵(18μg)吸入每天1次。观察两组治疗12、24周后肺功能、COPD评估测试量表(CAT)评分、血清C反应蛋白(CRP)水平变化。结果两组治疗12、24周后肺功能均较治疗前明显改善(P<0.05),治疗组改善程度优于对照组(P<0.05)。治疗后两组CAT评分均较治疗前显著下降(P<0.05),治疗组低于对照组(P<0.05)。治疗24周后治疗组血清CRP水平显著低于治疗前(P<0.05),治疗组低于对照组(P<0.05)。结论沙美特罗/丙酸氟替卡松与噻托溴铵联合吸入治疗能够有效改善重度稳定期COPD患者的肺功能及生活质量,降低血清CRP水平,疗效优于噻托溴铵单药吸入治疗。Objective To explore therapeutic effects of Salmeterol/Fluticasone Propionate combined with Tiotropium in treatment of patients with chronic obstructive pulmonary disease（COPD） during severe stable phase.Methods Sixty-nine patients with COPD during severe stable phase were randomly divided into therapy group（n = 35） and control group（n = 34）.The therapy group was treated with Salmeterol/Fluticasone Propionate inhalation（50 μg /250 μg,2 times a day）,and Tiotropium inhalation（18 μg,1 time a day）;the control group was treated only with Tiotropium inhalation（18 μg,1 time a day）.The lung function,scores of COPD assessment test（CAT） and changes of serum C-reactive protein（CRP） levels were respectively measured 12th and 24th weeks after treatment in the two groups.Results Lung function of the two groups were significantly improved 12th and 24th weeks after treatment compared with those before treatment（P 0.05）,and it was better in therapy group than that in control group（P 0.05）.After treatment,CAT scores in the two groups were significantly lower than those before treatment（P 0.05）,and which were lower in therapy group than those in control group（P 0.05）.The serum CRP level in therapy group 12th week after treatment was significantly lower than that before treatment,and which was significantly lower in therapy group than that in control group（P 0.05）.Conclusion Salmeterol/Fluticasone Propionate combined with Tiotropium inhalation may significantly improve lung function and quality of life in patients with COPD during severe stable phase and reduced CRP levels,and its therapeutic effects is better than that only by Tiotropium inhalation.

关 键 词：肺疾病 慢性阻塞性 沙美特罗 丙酸氟替卡松 噻托溴铵 

分 类 号：R563.9[医药卫生—呼吸系统]